Washington-based biotech company advances COVID-19 treatment trials

By Washington Examiner

Published July 7, 2020 4:00pm ET

Add Washington Examiner on Google

Washington-based biotech company advances COVID-19 treatment trials — In this Thursday, Feb. 6, 2020, photo, employees work in the pop-up Huoyan Laboratory specialized in the nucleic acid test on 2019-nCoV in Wuhan in central China's Hubei province. The coronavirus continues to spread as of Friday, Feb. 7, 2020, China reported more than 31,000 cases. | (Chinatopix via AP)

A potential COVID-19 treatment developed by a Washington-based biotech company is one step closer to nationwide distribution if clinical trials prove successful.

CytoDyn Inc. announced on Monday that it had reached an exclusive deal with pharmaceutical company American Regent to distribute one of its latest products, leronlimab, per approval by the Food and Drug Administration.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

COVID-19 Healthcare News Politics State News Vaccines Washington